LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Lista de Ações・ADMA Biologics Inc

ADMA Biologics Inc

Fechado

SetorSaúde

8.15 -3.44

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.08

Máximo

8.19

Indicadores-chave
By Trading Economics
Rendimento	13M 49M
Vendas	4.9M 139M
P/E Médio do Setor	17.475 49.8
EPS	0.216
Margem de lucro	35.483
Funcionários	640
EBITDA	14M 65M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+189.72% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.5B 2.4B
Abertura anterior	11.59
Fecho anterior	8.15

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

N/A / 23.5406 Suporte e Resistência

ADMA Biologics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 de mai. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 de mai. de 2026, 23:38 UTC

Conversa de Mercado

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 de mai. de 2026, 23:14 UTC

Conversa de Mercado

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 de mai. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 de mai. de 2026, 22:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 de mai. de 2026, 10:21 UTC

Ganhos

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 de mai. de 2026, 06:05 UTC

Ganhos

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Still Going Strong -- Barrons.com

8 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 20:49 UTC

Ganhos

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 de mai. de 2026, 20:25 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Net $115M

8 de mai. de 2026, 19:20 UTC

Conversa de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 de mai. de 2026, 19:18 UTC

Ganhos

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 de mai. de 2026, 19:16 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:08 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:05 UTC

Ganhos

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 de mai. de 2026, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 de mai. de 2026, 18:51 UTC

Ganhos

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 de mai. de 2026, 18:49 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 18:41 UTC

Ganhos

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 de mai. de 2026, 17:14 UTC

Ganhos

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 de mai. de 2026, 17:04 UTC

Conversa de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

ADMA Biologics Inc Previsão

Preço-alvo

By TipRanks

189.72% parte superior

Previsão para 12 meses

Média 23.67 USD 189.72%

Máximo 30 USD

Mínimo 20 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para ADMA Biologics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para ADMA Biologics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

N/A / 23.5406Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bullish event.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.